300181 Stock Overview
Engages in the research, production, and marketing of Chinese medicinal products in the People’s Republic of China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Zhejiang Jolly Pharmaceutical Co.,LTD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥15.79 |
| 52 Week High | CN¥18.30 |
| 52 Week Low | CN¥8.36 |
| Beta | 0.12 |
| 11 Month Change | 34.27% |
| 3 Month Change | 9.20% |
| 1 Year Change | 55.41% |
| 33 Year Change | 102.18% |
| 5 Year Change | 206.01% |
| Change since IPO | 277.21% |
Recent News & Updates
Investors Still Aren't Entirely Convinced By Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Earnings Despite 32% Price Jump
Oct 17
These 4 Measures Indicate That Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Is Using Debt Safely
Oct 06It's A Story Of Risk Vs Reward With Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)
Aug 30Recent updates
Investors Still Aren't Entirely Convinced By Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Earnings Despite 32% Price Jump
Oct 17These 4 Measures Indicate That Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Is Using Debt Safely
Oct 06It's A Story Of Risk Vs Reward With Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)
Aug 30We Ran A Stock Scan For Earnings Growth And Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Passed With Ease
Jul 29Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%
May 13A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)
May 08There's No Escaping Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Muted Earnings
Mar 01Shareholder Returns
| 300181 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 6.3% | -5.6% | -4.4% |
| 1Y | 55.4% | -3.6% | 0.05% |
Return vs Industry: 300181 exceeded the CN Pharmaceuticals industry which returned -3.6% over the past year.
Return vs Market: 300181 exceeded the CN Market which returned 0.1% over the past year.
Price Volatility
| 300181 volatility | |
|---|---|
| 300181 Average Weekly Movement | 8.2% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in CN Market | 11.3% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 300181 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300181's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 2,687 | Tao Wang | www.zuoli.com |
Zhejiang Jolly Pharmaceutical Co.,LTD engages in the research, production, and marketing of Chinese medicinal products in the People’s Republic of China and internationally. The company offers Wuling capsule that is used to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kidney, or neurasthenia. It also provides Lingze tablet, which is used to treat frequent urination, dysuria, weak steam of urine, endless urine, and soreness and weakness of waist and knees caused by benign prostatic hyperplasia, kidney deficiency, and blood stasis; and Bailing tablet that is used as the adjuvant therapy to treat cough, asthma, back pain, and chronic bronchitis, which are caused by the deficiency of lungs and kidney.
Zhejiang Jolly Pharmaceutical Co.,LTD Fundamentals Summary
| 300181 fundamental statistics | |
|---|---|
| Market cap | CN¥11.07b |
| Earnings (TTM) | CN¥481.33m |
| Revenue (TTM) | CN¥2.36b |
23.0x
P/E Ratio4.7x
P/S RatioIs 300181 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300181 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.36b |
| Cost of Revenue | CN¥839.85m |
| Gross Profit | CN¥1.52b |
| Other Expenses | CN¥1.04b |
| Earnings | CN¥481.33m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 28, 2024
| Earnings per share (EPS) | 0.69 |
| Gross Margin | 64.40% |
| Net Profit Margin | 20.40% |
| Debt/Equity Ratio | 8.9% |
How did 300181 perform over the long term?
See historical performance and comparison